Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model

Autophagy

Volumn 16, Issue 1, 2020, Pages 52-69

  Luo, Rongcan ^a,b   Su, Ling Yan ^a,c   Li, Guiyu ^a,b   Yang, Jing ^a,b   Liu, Qianjin ^a,b   Yang, Lu Xiu ^a   Zhang, Deng Feng ^a,c   Zhou, Hejiang ^a   Xu, Min ^a,b   Fan, Yu ^a   Li, Jiali ^a   Yao, Yong Gang ^a,b,d  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d Shenzhen Fundamental Research Institutions   (China)

Author keywords

Alzheimer disease; autophagy; A ; gemfibrozil; PPARA; Wy14643

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GEMFIBROZIL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MICROTUBULE ASSOCIATED PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; RAPAMYCIN; AMYLOID BETA PROTEIN; PPARA PROTEIN, HUMAN; PPARA PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ASTROCYTE; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DENDRITIC SPINE; ESCAPE LATENCY; FATTY ACID METABOLISM; GENE KNOCKDOWN; GLIOMA CELL; HIPPOCAMPAL TISSUE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MEMORY DISORDER; MENTAL DETERIORATION; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; RNA INTERFERENCE; SPATIAL MEMORY; AMYLOID PLAQUE; ANIMAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AUTOPHAGY; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICROGLIA; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; PPAR ALPHA;

EID: 85063947961     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2019.1596488     Document Type: Article

References (100)

1. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer‘s disease. Lancet. 2016 Jul 30;388(10043):505–517. PubMed PMID: 26921134.
2. Wang J, Gu BJ, Masters CL, et al. A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol. 2017 Sep 29;13(10):612–623. PubMed PMID: 28960209.
3. Querfurth HW, LaFerla FM., Alzheimer‘s disease. N Engl J Med. 2010 Jan 28;362(4):329–344. PubMed PMID: 20107219.
4. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer‘s disease. Science. 2010 Dec 24;330(6012):1774. PubMed PMID: 21148344; PubMed Central PMCID: PMC3073454.
5. Selkoe DJ, Hardy J., The amyloid hypothesis of Alzheimer‘s disease at 25 years. EMBO Mol Med. 2016 Jun;8(6):595–608. PubMed PMID: 27025652; PubMed Central PMCID: PMC4888851.
6. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016 Sep 1;537(7618):50–56. PubMed PMID: 27582220.
7. Bu XL, Xiang Y, Jin WS, et al. Blood-derived amyloid-beta protein induces Alzheimer‘s disease pathologies. Mol Psychiatry. 2017 Oct 31. PubMed PMID: 29086767. DOI:10.1038/mp.2017.204
8. Jin WS, Shen LL, Bu XL, et al. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol. 2017 Aug;134(2):207–220. PubMed PMID: 28477083.
9. Menzies FM, Fleming A, Rubinsztein DC. Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci. 2015 Jun;16(6):345–357. PubMed PMID: 25991442.
10. Chung KM, Hernandez N, Sproul AA, et al. Alzheimer‘s disease and the autophagic-lysosomal system. Neurosci Lett. 2018 May 18. pii: S0304-3940(18):30344-6. PubMed PMID: 29758300. DOI:10.1016/j.neulet.2018.05.017
11. Metaxakis A, Ploumi C, Tavernarakis N. Autophagy in age-associated neurodegeneration. Cells. 2018 May 5;7(5):pii: E37. PubMed PMID: 29734735; PubMed Central PMCID: PMC5981261.
12. Caccamo A, Majumder S, Richardson A, et al. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem. 2010 Apr 23;285(17):13107–13120. PubMed PMID: 20178983; PubMed Central PMCID: PMC2857107.
13. Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest. 2008 Jun;118(6):2190–2199. PubMed PMID: 18497889; PubMed Central PMCID: PMC2391284.
14. Swaminathan G, Zhu W, Plowey ED. BECN1/Beclin 1 sorts cell-surface APP/amyloid β precursor protein for lysosomal degradation. Autophagy. 2016 Dec;12(12):2404–2419. PubMed PMID: 27715386; PubMed Central PMCID: PMC5173276.
15. Xiao Q, Yan P, Ma X, et al. Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing Abeta generation and amyloid plaque pathogenesis. J Neurosci. 2015 Sep 2;35(35):12137–12151. PubMed PMID: 26338325; PubMed Central PMCID: PMC4556784.
16. Zhang YD, Zhao JJ. TFEB participates in the Aβ-induced pathogenesis of Alzheimer‘s disease by regulating the autophagy-lysosome pathway. DNA Cell Biol. 2015 Nov;34(11):661–668. PubMed PMID: 26368054.
17. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006 Jun 15;441(7095):885–889. PubMed PMID: 16625204.
18. Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006 Jun 15;441(7095):880–884. PubMed PMID: 16625205.
19. Yang DS, Stavrides P, Mohan PS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer‘s disease ameliorates amyloid pathologies and memory deficits. Brain. 2011 Jan;134(Pt 1):258–277. PubMed PMID: 21186265; PubMed Central PMCID: PMC3009842.
20. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol. 2011 Dec 20;8(2):108–117. PubMed PMID: 22187000.
21. Schaeffer V, Goedert M. Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy. Autophagy. 2012 Nov;8(11):1686–1687. PubMed PMID: 22874558; PubMed Central PMCID: PMC3494601.
22. Di Meco A, Li JG, Blass BE, et al. 12/15-Lipoxygenase inhibition reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice. Biol Psychiatry. 2017 Jan 15;81(2):92–100. PubMed PMID: 27499089.
23. Caccamo A, Ferreira E, Branca C, et al. p62 improves AD-like pathology by increasing autophagy. Mol Psychiatry. 2017 Jun;22(6):865–873. PubMed PMID: 27573878; PubMed Central PMCID: PMC5479312.
24. Frake RA, Ricketts T, Menzies FM, et al. Autophagy and neurodegeneration. J Clin Invest. 2015 Jan;125(1):65–74. PubMed PMID: 25654552; PubMed Central PMCID: PMC4382230.
25. Chauhan S, Ahmed Z, Bradfute SB, et al. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620. PubMed PMID: 26503418; PubMed Central PMCID: PMC4624223.
26. Keller H, Dreyer C, Medin J, et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2160–2164. PubMed PMID: 8384714; PubMed Central PMCID: PMC46045.
27. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998 Jun 25;393(6687):790–793. PubMed PMID: 9655393; PubMed Central PMCID: PMC 9655393.
28. Kersten S. Integrated physiology and systems biology of PPARalpha. Mol Metab. 2014 Jul;3(4):354–371. PubMed PMID: 24944896; PubMed Central PMCID: PMC4060217.
29. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004 Feb;61(4):393–416. PubMed PMID: 14999402.
30. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999 Jul 10;354(9173):141–148. PubMed PMID: 10408502.
31. Lee JM, Wagner M, Xiao R, et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 2014 Dec 4;516(7529):112–115. PubMed PMID: 25383539; PubMed Central PMCID: PMC4267857.
32. Kim YS, Lee HM, Kim JK, et al. PPAR-alpha activation mediates innate host defense through induction of TFEB and lipid catabolism. J Immunol. 2017 Apr 15;198(8):3283–3295. PubMed PMID: 28275133.
33. Kolsch H, Lehmann DJ, Ibrahim-Verbaas CA, et al. Interaction of insulin and PPAR-alpha genes in Alzheimer‘s disease: the Epistasis Project. J Neural Transm (Vienna). 2012 Apr;119(4):473–479. PubMed PMID: 22065208.
34. Corbett GT, Gonzalez FJ, Pahan K. Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8445–8450. PubMed PMID: 26080426; PubMed Central PMCID: PMC4500265.
35. Roy A, Jana M, Kundu M, et al. HMG-CoA reductase inhibitors bind to PPARalpha to upregulate neurotrophin expression in the brain and improve memory in mice. Cell Metab. 2015 Aug 4;22(2):253–265. PubMed PMID: 26118928; PubMed Central PMCID: PMC4526399.
36. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial Study group. N Engl J Med. 1999 Aug 5;341(6):410–418. PubMed PMID: 10438259; PubMed Central PMCID: PMC10438259.
37. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. PubMed PMID: 3313041; PubMed Central PMCID: PMC3313041.
38. Zhang DF, Li J, Wu H, et al. CFH variants affect structural and functional brain changes and genetic risk of Alzheimer’s disease. Neuropsychopharmacol. 2016 Mar;41(4):1034–1045. PubMed PMID: 26243271; PubMed Central PMCID: PMC4748428.
39. Rubinsztein DC, Cuervo AM, Ravikumar B, et al. In search of an “autophagomometer”. Autophagy. 2009 Jul;5(5):585–589. PubMed PMID: 19411822.
40. Feng L, Ma Y, Sun J, et al. YY1-MIR372-SQSTM1 regulatory axis in autophagy. Autophagy. 2014 Aug;10(8):1442–1453. PubMed PMID: 24991827; PubMed Central PMCID: PMC4203520.
41. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004 Jan 15;13(2):159–170. PubMed PMID: 14645205.
42. Giannopoulos PF, Chu J, Joshi YB, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer‘s disease. Mol Psychiatry. 2014 Apr;19(4):511–518. PubMed PMID: 23478745; PubMed Central PMCID: PMC3688674.
43. Giannopoulos PF, Chu J, Sperow M, et al. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry. 2015 Nov 15;78(10):693–701. PubMed PMID: 25802082; PubMed Central PMCID: PMC4529386.
44. Di Meco A, Joshi YB, Lauretti E, et al. Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice. Mol Psychiatry. 2016 Mar;21(3):403–410. PubMed PMID: 26077691.
45. Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry. 2015 Mar;72(3):284–291. PubMed PMID: 25629787.
46. Seibenhener ML, Wooten MC. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015 Feb 6;(96):e52434. PubMed PMID: 25742564; PubMed Central PMCID: PMC4354627. DOI:10.3791/52434
47. Attwood BK, Bourgognon JM, Patel S, et al. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature. 2011 May 19;473(7347):372–375. PubMed PMID: 21508957; PubMed Central PMCID: PMC3145099.
48. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. CSH Perspect Med. 2012 Jul;2(7):a006338–a006338. PubMed PMID: 22762015; PubMed Central PMCID: PMC3385944
49. Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014 Jan;112:24–49. PubMed PMID: 24211851.
50. Shao Y, Gearing M, Mirra SS. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J Neuropathol Exp Neurol. 1997 Apr;56(4):376–381. PubMed PMID: 9100668.
51. Pihlaja R, Koistinaho J, Malm T, et al. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer‘s disease. Glia. 2008 Jan 15;56(2):154–163. PubMed PMID: 18004725.
52. Nicoll JA, Weller RO. A new role for astrocytes: β-amyloid homeostasis and degradation. Trends Mol Med. 2003 Jul;9(7):281–282. PubMed PMID: 12900213.
53. McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987 Aug 18;79(1–2):195–200. PubMed PMID: 3670729.
54. Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer‘s disease. Neuron. 2006 Feb 16;49(4):489–502. PubMed PMID: 16476660.
55. Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist. 2015 Apr;21(2):169–184. PubMed PMID: 24722525; PubMed Central PMCID: PMC4412879.
56. Malm TM, Jay TR, Landreth GE. The evolving biology of microglia in Alzheimer‘s disease. Neurotherapeutics. 2014 Jan;12(1):81–93. PubMed PMID: 25404051; PubMed Central PMCID: PMC4322081.
57. Liu Z, Condello C, Schain A, et al. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J Neurosci. 2010 Dec 15;30(50):17091–17101. PubMed PMID: 21159979; PubMed Central PMCID: PMC3077120.
58. Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer‘s disease mouse models. Am J Pathol. 2010 Nov;177(5):2549–2562. PubMed PMID: 20864679; PubMed Central PMCID: PMC2966811.
59. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer‘s disease. Nat Immunol. 2015 Mar;16(3):229–236. PubMed PMID: 25689443.
60. Alves S, Churlaud G, Audrain M, et al. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer‘s disease mice. Brain. 2017 Mar 1;140(3):826–842. PubMed PMID: 28003243.
61. Zotova E, Bharambe V, Cheaveau M, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization. Brain. 2013 Sep;136(9):2677–2696. PubMed PMID: 23943781.
62. Guillot-Sestier MV, Doty KR, Gate D, et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 2015 Feb 4;85(3):534–548. PubMed PMID: 25619654; PubMed Central PMCID: PMC4352138.
63. Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer‘s disease model. Cell. 2015 Mar 12;160(6):1061–1071. PubMed PMID: 25728668; PubMed Central PMCID: PMC4477963.
64. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer‘s disease. J Alzheimers Dis. 2006 Jul;9(2):167–181. PubMed PMID: 16873964.
65. Combs CK, Bates P, Karlo JC, et al. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int. 2001 Nov-Dec;39(5–6):449–457. PubMed PMID: 11578780.
66. Inestrosa NC, Carvajal FJ, Zolezzi JM, et al. Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer‘s disease. J Alzheimers Dis. 2013;33(4):941–959. PubMed PMID: 23109558.
67. Lalonde R, Kim HD, Fukuchi K. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/ΔE9 mice. Neurosci Lett. 2004 Oct 14;369(2):156–161. PubMed PMID: 15450687.
68. Lalonde R, Kim HD, Maxwell JA, et al. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett. 2005 Dec 23;390(2):87–92. PubMed PMID: 16169151.
69. Reiserer RS, Harrison FE, Syverud DC, et al. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer‘s disease. Genes Brain Behav. 2007 Feb;6(1):54–65. PubMed PMID: 17233641.
70. Pugh PL, Richardson JC, Bate ST, et al. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer‘s disease. Behav Brain Res. 2007 Mar 12;178(1):18–28. PubMed PMID: 17229472.
71. Olesen LØ, Bouzinova EV, Severino M, et al. Behavioural phenotyping of APPswe/PS1δE9 mice: age-rrelated changes and effect of long-term paroxetine treatment. PLoS One. 2016 Nov 4;11(11):e0165144. PubMed PMID: 27814403; PubMed Central PMCID: PMC5096719.
72. Liu Y, Yoo MJ, Savonenko A, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer‘s disease. J Neurosci. 2008 Dec 17;28(51):13805–13814. PubMed PMID: 19091971.
73. Gao JY, Chen Y, Su DY, et al. Anxiety-like but not despair-like behaviors are further aggravated by chronic mild stress in the early stages of APPswe/PS1dE9 transgenic mice. BioRxiv. 2017 Oct 12. DOI:10.1101/202283
74. Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy–a novel Beta-amyloid peptide-generating pathway activated in Alzheimer‘s disease. J Cell Biol. 2005 Oct 10;171(1):87–98. PubMed PMID: 16203860; PubMed Central PMCID: PMC2171227.
75. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007 Dec 1;120(Pt 23):4081–4091. PubMed PMID: 18032783.
76. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013 Aug;19(8):983–997. PubMed PMID: 23921753.
77. Lucin KM, O‘Brien CE, Bieri G, et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer‘s disease. Neuron. 2013 Sep 4;79(5):873–886. PubMed PMID: 24012002; PubMed Central PMCID: PMC3779465.
78. Ghosh A, Jana M, Modi K, et al. Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem. 2015 Apr 17;290(16):10309–10324. PubMed PMID: 25750174; PubMed Central PMCID: PMC4400343.
79. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001 Mar 28;285(12):1585–1591. PubMed PMID: 11268266.
80. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004 Jul;10(7):719–726. PubMed PMID: 15195085.
81. Meyer-Luehmann M, Prinz M. Myeloid cells in Alzheimer‘s disease: culprits, victims or innocent bystanders? Trends Neurosci. 2015 Oct;38(10):659–668. PubMed PMID: 26442698.
82. Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010 Aug;117(8):949–960. PubMed PMID: 20552234; PubMed Central PMCID: PMCPMC3653296.
83. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005 May 27;308(5726):1314–1318. PubMed PMID: 15831717.
84. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron. 2009 Oct 15;64(1):110–122. PubMed PMID: 19840553; PubMed Central PMCID: PMC2834890.
85. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011 Sep 9;333(6048):1456–1458. PubMed PMID: 21778362.
86. Herber DL, Roth LM, Wilson D, et al. Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice. Exp Neurol. 2004 Nov;190(1):245–253. PubMed PMID: 15473997.
87. Herber DL, Mercer M, Roth LM, et al. Microglial activation is required for Aβ clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharm. 2007 Jun;2(2):222–231. PubMed PMID: 18040847.
88. DiCarlo G, Wilcock D, Henderson D, et al. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 2001 Nov-Dec;22(6):1007–1012. PubMed PMID: 11755009.
89. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer‘s disease. Lancet Neurol. 2015 Apr;14(4):388–405. PubMed PMID: 25792098; PubMed Central PMCID: PMC5909703.
90. Abeti R, Abramov AY, Duchen MR. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain. 2011 Jun;134(Pt 6):1658–1672. PubMed PMID: 21616968.
91. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer‘s disease mice. J Neurosci. 2008 Aug 13;28(33):8354–8360. PubMed PMID: 18701698; PubMed Central PMCID: PMC2597474.
92. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007 Apr;13(4):432–438. PubMed PMID: 17351623.
93. Kaifu T, Nakahara J, Inui M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest. 2003 Feb;111(3):323–332. PubMed PMID: 12569157; PubMed Central PMCID: PMC151867.
94. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001 Jul 13;293(5528):306–311. PubMed PMID: 11452127.
95. Wyss-Coray T, Yan F, Lin AHT, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer‘s mice. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837–10842. PubMed PMID: 12119423; PubMed Central PMCID: PMC125059.
96. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer‘s disease and contributes to pathology in APP/PS1 mice. Nature. 2013 Jan 31;493(7434):674–678. PubMed PMID: 23254930; PubMed Central PMCID: PMC3812809.
97. Su LY, Luo R, Liu Q, et al. Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine. Autophagy. 2017 Jul 19;13(9):1496–1511. PubMed PMID: 28722508; PubMed Central PMCID: PMC5612517.
98. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1–222. PubMed PMID: 26799652; PubMed Central PMCID: PMC4835977.
99. Burgess A, Vigneron S, Brioudes E, et al. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12564–12569. PubMed PMID: 20538976; PubMed Central PMCID: PMC2906566.
100. Krauthausen M, Kummer MP, Zimmermann J, et al. CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer‘s disease model. J Clin Invest. 2015 Jan;125(1):365–378. PubMed PMID: 25500888; PubMed Central PMCID: PMC4382235.